Literature DB >> 30190961

Management of hepatocellular carcinoma: time to be resilient.

Jean-Francois Dufour1.   

Abstract

Entities:  

Year:  2014        PMID： 30190961      PMCID： PMC6095163          DOI： 10.2217/hep.14.12

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  9 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference.

Authors:  Jean-François Dufour; Philip Johnson
Journal:  J Hepatol       Date:  2009-12-16       Impact factor: 25.083

3.  Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Carol E A Peña; Chetan D Lathia; Michael Shan; Gerold Meinhardt; Jordi Bruix
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

4.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

5.  Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor.

Authors:  E Vibert; D Azoulay; E Hoti; S Iacopinelli; D Samuel; C Salloum; A Lemoine; H Bismuth; D Castaing; R Adam
Journal:  Am J Transplant       Date:  2010-01       Impact factor: 8.086

6.  A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

Authors:  Jean-Charles Nault; Aurélien De Reyniès; Augusto Villanueva; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Thomas Decaens; Dominique Franco; Sandrine Imbeaud; Francis Rousseau; Daniel Azoulay; Jean Saric; Jean-Frédéric Blanc; Charles Balabaud; Paulette Bioulac-Sage; Alexis Laurent; Pierre Laurent-Puig; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2013-04-06       Impact factor: 22.682

Review 7.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

8.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316

9.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Authors:  Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.